Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Timmerman

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
International Journal of Hematology|July 5, 2003
Immunotherapy for lymphomasJohn M Timmerman
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Therapeutic idiotype vaccines for non-Hodgkin's lymphomaJohn M Timmerman
Current Treatment Options in Oncology|June 21, 2002
Vaccine therapies for non-Hodgkin's lymphomaJohn M Timmerman
Human Vaccines|February 28, 2009
Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses?John M Timmerman
Nature Medicine|February 1, 2005
Cancer vaccines: pessimism in checkJohn M Timmerman, Ronald Levy
Cancer Treatment and Research|May 18, 2006
Vaccine therapies for non-Hodgkin's lymphomasSarah Montross, John M Timmerman
Expert Opinion on Biological Therapy|June 15, 2005
Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavIdSara A Hurvitz, John M Timmerman
Current Opinion in Oncology|August 12, 2005
Current status of therapeutic vaccines for non-Hodgkin's lymphomaSara A Hurvitz, John M Timmerman
Expert Opinion on Biological Therapy|August 13, 2008
Interleukin-21: biology and application to cancer therapyDavid J Andorsky, John M Timmerman
Seminars in Oncology|December 3, 2014
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safetyPatricia A Young, Sherie L Morrison, John M Timmerman
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
International Journal of Hematology|July 5, 2003
Immunotherapy for lymphomasJohn M Timmerman
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Therapeutic idiotype vaccines for non-Hodgkin's lymphomaJohn M Timmerman
Current Treatment Options in Oncology|June 21, 2002
Vaccine therapies for non-Hodgkin's lymphomaJohn M Timmerman
Human Vaccines|February 28, 2009
Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses?John M Timmerman
Nature Medicine|February 1, 2005
Cancer vaccines: pessimism in checkJohn M Timmerman, Ronald Levy
Cancer Treatment and Research|May 18, 2006
Vaccine therapies for non-Hodgkin's lymphomasSarah Montross, John M Timmerman
Expert Opinion on Biological Therapy|June 15, 2005
Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavIdSara A Hurvitz, John M Timmerman
Current Opinion in Oncology|August 12, 2005
Current status of therapeutic vaccines for non-Hodgkin's lymphomaSara A Hurvitz, John M Timmerman
Expert Opinion on Biological Therapy|August 13, 2008
Interleukin-21: biology and application to cancer therapyDavid J Andorsky, John M Timmerman
Seminars in Oncology|December 3, 2014
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safetyPatricia A Young, Sherie L Morrison, John M Timmerman
Pageof 6